Ignite Creation Date:
2024-05-06 @ 6:57 PM
Last Modification Date:
2024-10-26 @ 2:58 PM
Study NCT ID:
NCT05847413
Status:
COMPLETED
Last Update Posted:
2023-05-06
First Post:
2023-04-27
Brief Title:
Targeting Beta Cell Dysfunction With Verapamil in Longstanding T1D
Sponsor:
Benaroya Research Institute
Organization:
Benaroya Research Institute
Study Overview
Official Title:
Targeting Beta Cell Dysfunction With Verapamil in Longstanding T1D
Status:
COMPLETED
Status Verified Date:
2023-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine whether verapamil can transiently improve beta cell function in those who do or do not secrete proinsulin and littleno C-peptide
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None